Bluebird Bio Issues LYFGENIA Boxed Warning: Hematologic Malignancy Has Occurred In Patients Treated With The Drug; Patients Should Monitor For Evidence Of Malignancy Through Complete Blood Counts At Least Every 6 Months, Through Integration Site Analysis
Bluebird Bio Issues LYFGENIA Boxed Warning: Hematologic Malignancy Has Occurred In Patients Treated With The Drug; Patients Should Monitor For Evidence Of Malignancy Through Complete Blood Counts At Least Every 6 Months, Through Integration Site Analysis
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.